In 2025, the company achieved U.S. and European regulatory approvals for the GenesisX robot, the MAGiC ablation catheter, and the MAGiC Sweep high-density mapping catheter. Fischel described these approvals as a key foundation for the company’s initial commercial focus in complex EP procedures, including congenital heart disease, pediatrics, and ventricular tachycardia. He also cited EP as a large and growing market, stating it treats approximately 2 million patients annually and generates more than $13 bil ...